Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study

托法替尼 类风湿性关节炎 医学 内科学 队列
作者
Ajinkya Pawar,Rishi Desai,Nileesa Gautam,Seoyoung C. Kim
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:2 (2): e84-e98 被引量:51
标识
DOI:10.1016/s2665-9913(19)30137-7
摘要

Background The risk of serious infection is a major concern when prescribing a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. Little evidence exists with regard to serious infection risk associated with tofacitinib, a targeted synthetic (ts)DMARD, compared with biologic DMARDs (bDMARDs) among patients with rheumatoid arthritis. We compared the risk of serious infection in patients with rheumatoid arthritis initiating tofacitinib versus one of the seven bDMARDs. Methods In this multidatabase cohort study, we identified eight mutually exclusive groups of patients with rheumatoid arthritis initiating tofacitinib or one of the seven bDMARDs using US public (Medicare 20012–15) and private (Optum Clinformatics 2012–18 and IBM MarketScan 2012–17) health insurance programmes. Eligible patients were aged 18 years or older, and had one inpatient visit or two or more outpatient visits (7–365 days apart) for rheumatoid arthritis using International Classification of Diseases 9th and 10th revision codes. The primary outcome was a composite endpoint of admission to hospital for serious infection including bacterial, viral, or opportunistic infection based on the inpatient principal diagnosis code. Secondary outcomes were individual types of serious infections and herpes zoster. We adjusted for more than 60 potential confounders through propensity score-based inverse probability treatment weighting in each database. Database-specific adjusted hazard ratios (aHRs) were combined using a fixed-effects meta-analysis. Findings We identified 130 718 patients with rheumatoid arthritis across the three databases. During 100 790 person-years of follow-up, 3140 serious infections occurred (crude incidence rate per 100 person-years 3·12, 95% CI 3·01–3·23). The aHR for serious infection associated with tofacitinib was 1·41 (95% CI 1·15–1·73) versus etanercept, 1·20 (0·97–1·49) versus abatacept, 1·23 (0·94–1·62) versus golimumab, and 1·17 (0·89–1·53) versus tocilizumab. The serious infection risk with tofacitinib was similar to adalimumab (1·06, 0·87–1·30) and certolizumab (1·02, 0·80–1·29), and was lower than infliximab (0·81, 0·65–1·00). Tofacitinib was associated with a 2-fold higher risk of herpes zoster versus all bDMARDs. Interpretation This study found potential differences between tofacitinib and several bDMARDs in the risk of admission to hospital for serious infection, as well as herpes zoster, in patients with rheumatoid arthritis. These results contribute to the evolving understanding of the overall risk-benefit profile of tofacitinib. Funding Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Harvard University, MA, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方应助钠钾蹦采纳,获得10
刚刚
似水流年完成签到,获得积分10
4秒前
wy.he应助科研通管家采纳,获得10
5秒前
wy.he应助科研通管家采纳,获得10
5秒前
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
wy.he应助科研通管家采纳,获得10
5秒前
7秒前
念0完成签到 ,获得积分10
11秒前
Jun完成签到 ,获得积分10
14秒前
我是弱智先帮我完成签到,获得积分10
15秒前
科研通AI5应助Heartune采纳,获得30
15秒前
于是完成签到,获得积分10
16秒前
香蕉觅云应助航1采纳,获得10
18秒前
科研小天才完成签到,获得积分10
22秒前
22秒前
研友_LX66qZ完成签到,获得积分10
23秒前
23秒前
Heartune发布了新的文献求助30
27秒前
OMR123完成签到,获得积分10
28秒前
小章鱼发布了新的文献求助10
28秒前
木云浅夏完成签到,获得积分10
33秒前
35秒前
航1发布了新的文献求助10
38秒前
Zoe完成签到,获得积分10
46秒前
pluto应助午休采纳,获得10
50秒前
52秒前
钠钾蹦发布了新的文献求助10
56秒前
57秒前
李爱国应助Misea采纳,获得10
59秒前
ningwu完成签到,获得积分10
59秒前
小牛同志完成签到,获得积分10
1分钟前
坚果完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
此时此刻完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
yuntong完成签到 ,获得积分0
1分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
Mixing the elements of mass customisation 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3779743
求助须知:如何正确求助?哪些是违规求助? 3325210
关于积分的说明 10221856
捐赠科研通 3040345
什么是DOI,文献DOI怎么找? 1668745
邀请新用户注册赠送积分活动 798775
科研通“疑难数据库(出版商)”最低求助积分说明 758549